Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2961253 | 0.85 | SMN1; SMN2 (0.66) | ALDH1A1CHRM4KDM4ELMNAL3MBTL1 | |
| SCHEMBL2959440 | 0.83 | CHRM4 (0.66) | ALDH1A1CHRM4POLBL3MBTL1MEN1 | |
| SCHEMBL3218052 | 0.83 | HSD11B1 (0.66) | ALDH1A1CHRM4 | |
| SCHEMBL2960545 | 0.82 | ALDH1A1 (0.75) | ALDH1A1POLBKDM4ELMNAMAPT | |
| SCHEMBL5251477 | 0.82 | KDM4E (0.76) | ALDH1A1POLBKDM4ELMNAMAPT | |
| SCHEMBL10723724 | 0.81 | CHRM4 (0.64) | ALDH1A1CHRM4POLBLMNAMAPT | |
| SCHEMBL4324132 | 0.81 | KDM4E (0.79) | ALDH1A1POLBKDM4ELMNAMAPT | |
| SCHEMBL13489664 | 0.80 | MEN1 (0.74) | ALDH1A1POLBKDM4ELMNAMAPT | |
| SCHEMBL2953059 | 0.79 | CHRM4 (0.53) | ALDH1A1CHRM4 | |
| SCHEMBL3224518 | 0.79 | HSD11B1 (0.65) | ALDH1A1CHRM4L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759339-B2 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-07-20 | — | — | US | claimed |
| EP-1866298-A2 | HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006105127-A2 | HYDROXYSTEROID DEHYDROGENASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-10-05 | — | — | WO | claimed |
| US-20060223829-A1 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-10-05 | — | — | US | claimed |
| US-7759339-B2 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759339-B2 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759339-B2 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| EP-1866298-A2 | HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006105127-A2 | HYDROXYSTEROID DEHYDROGENASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060223829-A1 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223829-A1 | Hydroxysteroid dehydrogenase inhibitors | HSD17B1, HSD17B3, HSD17B2 | ALDH1A1 82/4885CHRM4 4346/4885POLB 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.